Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127559812 | 12755981 | 2 | F | 20150527 | 20160919 | 20160916 | 20160921 | EXP | GXKR2016DE004182 | SANDOZ | 44.00 | YR | F | Y | 74.00000 | KG | 20160922 | MD | DE | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127559812 | 12755981 | 1 | PS | FILGRASTIM | FILGRASTIM | 1 | Subcutaneous | 30 MG, QD | 125553 | 30 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127559812 | 12755981 | 1 | Prophylaxis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127559812 | 12755981 | HO |
| 127559812 | 12755981 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127559812 | 12755981 | Asthenia | |
| 127559812 | 12755981 | Dyspnoea exertional | |
| 127559812 | 12755981 | General physical health deterioration | |
| 127559812 | 12755981 | Malignant neoplasm progression | |
| 127559812 | 12755981 | Multiple organ dysfunction syndrome | |
| 127559812 | 12755981 | Nausea |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127559812 | 12755981 | 1 | 20150203 | 0 |